JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma

  • 0Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital (Lihuili Hospital Affiliated to Ningbo University), Ningbo, China.
Aging +

|

June 8, 2024

|

June 8, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies a new signature of anoikis-related long noncoding RNAs (ARLRs) for predicting lung adenocarcinoma (LUAD) patient outcomes. Low-risk patients showed improved prognosis and immune cell infiltration, suggesting ARLRs as potential therapeutic targets.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Lung adenocarcinoma (LUAD) presents a significant global health challenge with high mortality rates.
  • Anoikis, a form of programmed cell death, plays a critical role in tumor progression, yet its associated long noncoding RNAs (lncRNAs) in LUAD remain underexplored.
  • Understanding the role of anoikis-related lncRNAs (ARLRs) is crucial for developing novel prognostic and therapeutic strategies for LUAD.

Purpose Of The Study

  • To identify and validate a prognostic signature of ARLRs in lung adenocarcinoma.
  • To investigate the correlation between the ARLR signature and clinical outcomes, immune microenvironment, and drug sensitivity in LUAD patients.
  • To explore the functional role of a specific ARLR in LUAD cell migration and invasion.

Main Methods

  • Utilized The Cancer Genome Atlas (TCGA) database for genomic and clinical data analysis.
  • Employed coexpression analysis and Cox regression to establish a prognostic ARLR signature.
  • Validated the signature using Kaplan-Meier (K-M) curves, receiver operating characteristic (ROC) curves, and nomogram construction.
  • Performed functional enrichment analysis and in vitro experiments to assess ARLR function.

Main Results

  • A novel prognostic signature comprising specific ARLRs was developed and validated for LUAD.
  • Patients in the low-risk group exhibited significantly improved prognosis, enhanced immune cell infiltration, and higher immune scores.
  • Distinct anticancer drug sensitivities were observed between the high-risk and low-risk groups, offering potential therapeutic guidance.
  • In vitro experiments confirmed the role of AC026355.2 in modulating LUAD cell migration and invasion.

Conclusions

  • The identified ARLR signature serves as a potential independent prognostic biomarker for LUAD patients.
  • ARLRs are implicated in LUAD progression, immune infiltration, and drug response, highlighting their therapeutic relevance.
  • This study provides a foundation for further research into ARLRs as therapeutic targets and prognostic indicators in lung adenocarcinoma.

Keywords: